Skip to main content
. Author manuscript; available in PMC: 2015 Oct 21.
Published in final edited form as: Vaccine. 2014 Sep 20;32(46):6039–6048. doi: 10.1016/j.vaccine.2014.09.021

Figure 3. Systemic immune response to LCMV-GP33 peptide.

Figure 3

C57BL/6 mice (5 mice/group) were challenged subcutaneously with TC-1 tumor cells and subsequently treated with various combinations of cisplatin, CpG and GP33 peptide as shown. The PBMCs were analyzed 1 week after the last antigen delivery. The presence of GP33-specific CD8+ T cells in PBMCs was analyzed using intracellular cytokine staining for IFN-γ and CD8+ staining followed by flow cytometry analysis. A. Representative flow cytometry contour plot depicting the frequency of IFN-γ-secreting CD8+ T cells among PBMCs after being pulsed with GP33 peptide. B. Bar graph depicting the number of IFN-γ+ CD8+ T cells among PBMCs (mean ±S.E).